This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Stocks Under $10: Not Right at Rite Aid

In's proprietary screening model, Rite Aid doesn't score well in its fundamentals. The company has failed to reach the 6% level in same-store sales growth for the last three months, while WalGreen has successfully hit double digits in each of the three months. With $4 billion in debt and a consolidating industry landscape, Rite Aid may have a hard time keeping up. Rite Aid spent $313.5 million last year to service its debt load, putting a further dent in its earnings power going forward.

Rite Aid is also a disaster in our alpha-factor category -- the potential of a stock to surge. Wal-Mart (WMT) is a growing player in this space and with more prescriptions being filled online, competition is as tough as ever. CVS and Walgreen are expected to expand operations in California, where Longs and Rite Aid currently hold the top two spots. Although Rite Aid is looking to open 75 stores in the coming year through a mix of relocation and new-store construction, Walgreen plans to begin construction on 400 new stores and CVS on 200 during this same period.

Not exactly the dynamic to warrant a premium valuation here. So the company is struggling, but what about the stock? Priced at less than $5 a share and with $16.6 billion in sales last year, maybe there is some value there, right?

Wrong. When Duane Reade announced it was being bought last December at 10 times enterprise value to estimated EBITDA, the industry benchmark, Rite Aid shares quickly traded up to 9.5 times EV/EBITDA. But the stock has since declined to 7.8 times EV/EBITDA, in line with industry leader CVS, which has grown sales at close to 11% over the past five years, more than double the rate of growth turned in by Rite Aid.

With no catalyst on the horizon to spark top-line growth and limited capital to defend its industry position, another run-up in the stock price does not appear likely. Short interest represents only 2.9% of the float, limiting the impact a short squeeze could have, making this stock best avoided here at $4.64. And if you do own it, it is an ideal candidate to sell to raise some cash. There are better opportunities out there.

This article was written by Stocks Under $10 Investment Team, David Peltier and William Gabrielski.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs